Cargando…
Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars
Hypertrophic scars (HSs) and keloids are histologically characterized by excessive extracellular matrix (ECM) deposition. ECM deposition depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteases (TIMPs). TIMP-1 has been linked to ECM degradation and is...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486579/ https://www.ncbi.nlm.nih.gov/pubmed/32911344 http://dx.doi.org/10.1016/j.omtn.2020.08.005 |
_version_ | 1783581351223492608 |
---|---|
author | Aoki, Masayo Matsumoto, Noriko M. Dohi, Teruyuki Kuwahawa, Hiroaki Akaishi, Satoshi Okubo, Yuri Ogawa, Rei Yamamoto, Hirofumi Takabe, Kazuaki |
author_facet | Aoki, Masayo Matsumoto, Noriko M. Dohi, Teruyuki Kuwahawa, Hiroaki Akaishi, Satoshi Okubo, Yuri Ogawa, Rei Yamamoto, Hirofumi Takabe, Kazuaki |
author_sort | Aoki, Masayo |
collection | PubMed |
description | Hypertrophic scars (HSs) and keloids are histologically characterized by excessive extracellular matrix (ECM) deposition. ECM deposition depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteases (TIMPs). TIMP-1 has been linked to ECM degradation and is therefore a promising therapeutic strategy. In this study, we generated super carbonate apatite (sCA) nanoparticle-encapsulated TIMP-1 small interfering RNA (siRNA) (siTIMP1) preparations and examined the effect of local injections on mouse HSs and on ex vivo-cultured keloids. The sCA-siTIMP1 injections significantly reduced scar formation, scar cross-sectional areas, collagen densities, and collagen types I and III levels in the lesions. None of the mice died or exhibited abnormal endpoints. Apatite accumulation was not detected in the other organs. In an ex vivo keloid tissue culture system, sCA-siTIMP1 injections reduced the thickness and complexity of collagen bundles. Our results showed that topical sCA-siTIMP1 injections during mechanical stress-induced HS development reduced scar size. When keloids were injected three times with sCA-siTIMP1 during 6 days, keloidal collagen levels decreased substantially. Accordingly, sCA-siRNA delivery may be an effective approach for keloid treatment, and further investigations are needed to enable its practical use. |
format | Online Article Text |
id | pubmed-7486579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-74865792020-09-28 Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars Aoki, Masayo Matsumoto, Noriko M. Dohi, Teruyuki Kuwahawa, Hiroaki Akaishi, Satoshi Okubo, Yuri Ogawa, Rei Yamamoto, Hirofumi Takabe, Kazuaki Mol Ther Nucleic Acids Original Article Hypertrophic scars (HSs) and keloids are histologically characterized by excessive extracellular matrix (ECM) deposition. ECM deposition depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteases (TIMPs). TIMP-1 has been linked to ECM degradation and is therefore a promising therapeutic strategy. In this study, we generated super carbonate apatite (sCA) nanoparticle-encapsulated TIMP-1 small interfering RNA (siRNA) (siTIMP1) preparations and examined the effect of local injections on mouse HSs and on ex vivo-cultured keloids. The sCA-siTIMP1 injections significantly reduced scar formation, scar cross-sectional areas, collagen densities, and collagen types I and III levels in the lesions. None of the mice died or exhibited abnormal endpoints. Apatite accumulation was not detected in the other organs. In an ex vivo keloid tissue culture system, sCA-siTIMP1 injections reduced the thickness and complexity of collagen bundles. Our results showed that topical sCA-siTIMP1 injections during mechanical stress-induced HS development reduced scar size. When keloids were injected three times with sCA-siTIMP1 during 6 days, keloidal collagen levels decreased substantially. Accordingly, sCA-siRNA delivery may be an effective approach for keloid treatment, and further investigations are needed to enable its practical use. American Society of Gene & Cell Therapy 2020-08-08 /pmc/articles/PMC7486579/ /pubmed/32911344 http://dx.doi.org/10.1016/j.omtn.2020.08.005 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Aoki, Masayo Matsumoto, Noriko M. Dohi, Teruyuki Kuwahawa, Hiroaki Akaishi, Satoshi Okubo, Yuri Ogawa, Rei Yamamoto, Hirofumi Takabe, Kazuaki Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars |
title | Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars |
title_full | Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars |
title_fullStr | Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars |
title_full_unstemmed | Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars |
title_short | Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars |
title_sort | direct delivery of apatite nanoparticle-encapsulated sirna targeting timp-1 for intractable abnormal scars |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486579/ https://www.ncbi.nlm.nih.gov/pubmed/32911344 http://dx.doi.org/10.1016/j.omtn.2020.08.005 |
work_keys_str_mv | AT aokimasayo directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT matsumotonorikom directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT dohiteruyuki directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT kuwahawahiroaki directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT akaishisatoshi directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT okuboyuri directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT ogawarei directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT yamamotohirofumi directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars AT takabekazuaki directdeliveryofapatitenanoparticleencapsulatedsirnatargetingtimp1forintractableabnormalscars |